These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 1696653

  • 21. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadváry P.
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [Abstract] [Full Text] [Related]

  • 22. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 23. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 24. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S, Saito T, Otake A, Owada T, Mitsugi M, Hashimoto H, Maruyama Y.
    Arterioscler Thromb; 1993 Apr; 13(4):563-70. PubMed ID: 8385480
    [Abstract] [Full Text] [Related]

  • 25. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [Abstract] [Full Text] [Related]

  • 26. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
    Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D.
    Circulation; 1988 Mar; 77(3):670-7. PubMed ID: 3124974
    [Abstract] [Full Text] [Related]

  • 27. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
    Rebello SS, Huang J, Saito K, Saucedo JF, Bates ER, Lucchesi BR.
    Eur J Pharmacol; 1999 Jun 25; 374(3):399-410. PubMed ID: 10422784
    [Abstract] [Full Text] [Related]

  • 28. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Sep 25; 16(3):714-22. PubMed ID: 2117620
    [Abstract] [Full Text] [Related]

  • 29. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar 25; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor.
    Torr SR, Haskel EJ, VonVoigtlander PF, Bergmann SR, Abendschein DR.
    J Am Coll Cardiol; 1991 Dec 25; 18(7):1804-10. PubMed ID: 1960333
    [Abstract] [Full Text] [Related]

  • 31. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT.
    J Clin Invest; 1990 Oct 25; 86(4):1095-102. PubMed ID: 2145320
    [Abstract] [Full Text] [Related]

  • 32. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep 25; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 33. Evidence for a reversible oxygen radical-mediated component of reperfusion injury: reduction by recombinant human superoxide dismutase administered at the time of reflow.
    Ambrosio G, Weisfeldt ML, Jacobus WE, Flaherty JT.
    Circulation; 1987 Jan 25; 75(1):282-91. PubMed ID: 3791610
    [Abstract] [Full Text] [Related]

  • 34. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
    Fitzgerald DJ, Fitzgerald GA.
    Proc Natl Acad Sci U S A; 1989 Oct 25; 86(19):7585-9. PubMed ID: 2508092
    [Abstract] [Full Text] [Related]

  • 35. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs.
    Yao SK, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson HV, Panet A, Gorecki M, Buja LM.
    Circulation; 1994 Jun 25; 89(6):2822-8. PubMed ID: 8205697
    [Abstract] [Full Text] [Related]

  • 36. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May 25; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 37. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ, Hanson M, FitzGerald GA.
    J Clin Invest; 1991 Nov 25; 88(5):1589-95. PubMed ID: 1939647
    [Abstract] [Full Text] [Related]

  • 38. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H.
    Circulation; 1995 Feb 15; 91(4):1175-81. PubMed ID: 7850956
    [Abstract] [Full Text] [Related]

  • 39. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
    Miyazaki A, Tadokoro H, Drury JK, Rydén L, Haendchen RV, Corday E.
    J Am Coll Cardiol; 1991 Aug 15; 18(2):613-20. PubMed ID: 1906906
    [Abstract] [Full Text] [Related]

  • 40. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
    Saito T, Saitoh S, Asakura T, Kanke M, Owada K, Maruyama Y.
    Int J Cardiol; 1993 Mar 15; 38(3):225-33. PubMed ID: 8463004
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.